Inclisiran: a new generation of lipid-lowering siRNA therapeutic

Atherosclerotic heart disease (AHD) is a major cause of morbidity and mortality worldwide. Lowering low-density lipoprotein cholesterol (LDL-C) levels is a key strategy to prevent and treat AHD. Inclisiran is a novel siRNA drug that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yanzhen, Chen, Huaigang, Hong, Lang, Wang, Hong, Li, Bin, Zhang, Mengyin, Li, Jiamei, Yang, Liu, Liu, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611522/
https://www.ncbi.nlm.nih.gov/pubmed/37900173
http://dx.doi.org/10.3389/fphar.2023.1260921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611522/
https://www.ncbi.nlm.nih.gov/pubmed/37900173
http://dx.doi.org/10.3389/fphar.2023.1260921

Ejemplares similares